fingolimod mylan
mylan ireland limited - fingolimod stutt og long-term - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
eplerenon bluefish filmuhúðuð tafla 25 mg
bluefish pharmaceuticals ab - eplerenonum inn - filmuhúðuð tafla - 25 mg
eplerenone alvogen filmuhúðuð tafla 50 mg
alvogen ehf. - eplerenonum inn - filmuhúðuð tafla - 50 mg
amlodipin bluefish tafla 10 mg
bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 10 mg
eplerenon krka filmuhúðuð tafla 50 mg
krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 50 mg
metformin bluefish filmuhúðuð tafla 1000 mg
bluefish pharmaceuticals ab - metforminum hýdróklóríð - filmuhúðuð tafla - 1000 mg
bisoprolol medical valley filmuhúðuð tafla 5 mg
medical valley invest ab - bisoprololum fúmarat - filmuhúðuð tafla - 5 mg
carvedilol alvogen (carveratio) tafla 25 mg
alvogen ehf. - carvedilolum inn - tafla - 25 mg
amló tafla 5 mg
teva b.v.* - amlodipinum besýlat - tafla - 5 mg
amló tafla 10 mg
teva b.v.* - amlodipinum besýlat - tafla - 10 mg